WuXi Biologics Clears Two-Week Unannounced FDA Inspection

This latest regulatory clearance reinforces the company’s position in the global biopharmaceutical market, where the Mashan site maintains a historical record of over 600 successful client and agency audits. As the first biopharmaceutical facility in China to receive both FDA and EMA approval for commercial production, the site functions as a critical hub for integrated drug substance and drug product manufacturing. The facility currently supports the global launch of more than 20 biologics, leveraging its end-to-end service platform to streamline complex technology transfers and process scale-ups.

CEO Dr. Chris Chen noted that the successful inspection validates the company's internal quality systems amid tightening global regulatory expectations. With 49 regulatory inspections passed and 166 facility license approvals secured as of June 2026, the company continues to expand its reach. WuXi Biologics now manages a global network encompassing 26 drug substance facilities and 19 drug product facilities, supporting over 1,000 integrated client projects worldwide.